FDA Grants Accelerated Approval to Boehringer’s HERNEXEOS for HER2-Mutant Lung Cancer
The U.S. Food and Drug Administration (FDA) has granted accelerated approval to HERNEXEOS (zongertinib tablets), Boehringer Ingelheim’s new oral targeted therapy for adults with…
Read More...
Read More...
